VRTXVertex Pharmaceuticals Inc

CSNasdaq (XNAS)·USD

Identity

Security key: 23465
Ticker: VRTX
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 1991-07-31
Round lot: 40
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: VRTX

Detail

Enriched 2026-08-14 20:47

Market cap: $133,252,011,574.52
Shares outstanding (class): 253,805,417
Shares outstanding (weighted): 253,460,924
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 6,400
Location: BOSTON, MA
Homepage: https://www.vrtx.com
Description: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Market cap and share counts drift.

Funds holding this security

566 funds · 580 positions · $33.42B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$3.60B	0.18%	8,069,219 NS	FIGI
VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS	VOO	$2.88B	0.20%	6,455,161 NS	FIGI
Investment Co of America Investment Co of America	—	$2.80B	1.69%	6,269,142 NS	FIGI
American Balanced Fund American Balanced Fund	—	$2.65B	1.00%	5,930,918 NS	FIGI
Invesco QQQ Trust, Series 1 Invesco QQQ Trust, Series 1	QQQ	$2.39B	0.64%	5,351,474 NS	FIGI
New Perspective Fund New Perspective Fund	—	$1.50B	0.98%	3,366,011 NS	FIGI
iShares Core S&P 500 ETF iShares Trust	IVV	$1.46B	0.20%	3,266,609 NS	FIGI
N/A —	—	$1.32B	0.20%	2,965,418 NS	FIGI
VANGUARD GROWTH INDEX FUND VANGUARD INDEX FUNDS	VUG	$1.25B	0.39%	2,788,745 NS	FIGI
State Street(R) Health Care Select Sector SPDR(… SELECT SECTOR SPDR TRUST	XLV	$825.37M	2.14%	1,848,362 NS	FIGI
Growth Fund AMERICAN FUNDS INSURANCE SERIES	—	$691.51M	1.39%	1,548,600 NS	FIGI
Growth-Income Fund AMERICAN FUNDS INSURANCE SERIES	—	$654.01M	1.60%	1,464,610 NS	FIGI
VANGUARD INSTITUTIONAL INDEX FUND VANGUARD INSTITUTIONAL INDEX FUNDS	—	$639.53M	0.20%	1,432,189 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$604.63M	7.44%	1,354,033 NS	FIGI
JPMorgan Equity Premium Income ETF J.P. Morgan Exchange-Traded Fund Trust	JEPI	$543.77M	1.24%	1,217,752 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERVRTX
FIGI_COMPOSITEBBG000C1S2X2
FIGI_SHARE_CLASSBBG001S68LJ8
CIK0000875320
ISINUS92532F1003
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Vertex Pharmaceuticals is a biopharmaceutical company focused on medicines for cystic fibrosis, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.